Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nakai E et al. – The authors identified the crossreactivity of CD133 and MDR1 in a surgical specimen of GBM. The results suggest that CS cells may be resistant to current chemotherapy and represent a novel target for GBM therapeutics.



Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address